Introduction and objectives

Transcatheter edge-to-edge repair (TEER) should be considered in patients with heart failure and secondary mitral regurgitation (MR). Angiotensin receptor-neprilysin inhibitors (ARNIs) have been demonstrated to improve prognosis in heart failure. We aimed to evaluate the impact ARNIs on patient selection and outcomes.


The population of the Spanish TEER prospective registry (March 2012 to January 2021) was divided into 2 groups: a) TEER before the ARNI era (n = 450) and b) TEER after the recommendation of ARNIs by European Guidelines (n = 639), with further analysis according to intake (n = 52) or not (n = 587) of ARNIs.


A total of 1089 consecutive patients underwent TEER for secondary MR. In the ARNI era, there was a reduction in left ventricle dilation (82 mL vs 100 mL, P = .025), and better function (35% vs 38%, P = .011). At 2 years of follow-up, mortality (10.6% vs 17.3%, P < .001) and heart failure readmissions (16.6% vs 27.8%, P < .001) were lower in the ARNI era, but not recurrent MR. In the ARNI era, 1- and 2-year mortality were similar irrespective of ARNI intake but patients on ARNIs had a lower risk of readmission + mortality at 2 years (OR, 0.369; 95%CI, 0.137-0.992; P = .048), better NYHA class, and lower recurrence of MR III-IV (1.9% vs 14.3%, P = .011).


Better patient selection for TEER has been achieved in the last few years with a parallel improvement in outcomes. The use of ARNIs was associated with a significant reduction in overall events, better NYHA class, and lower MR recurrence.

Enlace a ScienceDirect. Más información


We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site